Access
To read this story in full you will need to login or make a payment (see right).
News
Nature Medicine 12, 719 (2006)
Published online: 28 June 2006 | doi:10.1038/nm0706-719b
NIH scandal underscores lack of sample oversight
Meredith Wadman1
- Washington, DC
Abstract
The example of the researcher who sold tissue samples to Pfizer raises serious questions.
Pay a visit to the website of The Cancer Genome Atlas, and you'll find this reassuring statement about the samples scientists hope to obtain for the project: "Tissue samples will be carefully catalogued, processed, checked for quality and stored, complete with important medical information about the patient."The information will have limits, the website hastens to add, and "samples will be coded to remove any descriptors that might connect a sample with the patient's private information.
To read this story in full you will need to login or make a payment (see right).
